Session

25.03.2021     16:00–16:45

Title:
Poster session 2
Antivirals and resistance I
Type:
ePoster session

25.03.2021
16:00–16:45

Title:
Poster session 2
Antivirals and resistance I
Type:
ePoster session


16:00–16:05
PS 90 The statin fluvastatin mitigates SARS-CoV-2 infection in human lung cells independently of its cholesterol lowering activity
Francisco José Zapatero Belinchón (Hannover/DE)
Talk time: 3 + 2 min


16:05–16:10
PS 91 Therapeutic potential of Cyclosporin A against SARS-CoV-2-infection
Lucie Sauerhering (Marburg/DE)
Talk time: 3 + 2 min


16:10–16:15
PS 92 Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection
Lukas Wettstein (Ulm/DE)
Talk time: 3 + 2 min


16:15–16:20
PS 93 From the plant to the antiviral extract - kuwanon G activity on human coronavirus and respiratory viruses
Mihayl Varbanov (Vandoeuvre les Nancy/FR)
Talk time: 3 + 2 min


16:20–16:25
PS 94 The novel influenza A virus defective interfering Particle "OP7" for antiviral treatment of influenza and COVID-19
Sascha Y. Kupke (Magdeburg/DE)
Talk time: 3 + 2 min


16:25–16:30
PS 95 Monitoring influenza viruses for reduced susceptibility to antiviral drugs
Susanne Duwe (Berlin/DE)
Talk time: 3 + 2 min


16:30–16:35
PS 96 Effect of influenza virus polymerase mutations on sensitivity to baloxavir marboxil
Brady T. Hickerson (Silver Spring/US)
Talk time: 3 + 2 min


16:35–16:40
PS 97 Measles virus infections of primary PBMC and neural stem cells (NT2) as model systems to investigate anti-viral compounds
Janice Chithelen (Würzburg/DE)
Talk time: 3 + 2 min


16:40–16:45
PS 98 Amino acid substitutions in viral RNA-dependent RNA polymerase associated with ribavirin non-responsiveness in patients with persistent genotype 4 hepatitis E virus infection
Siddharth Sridhar (Hong Kong/HK)
Talk time: 3 + 2 min